Last reviewed · How we verify

Ketorolac 30 mg

Cairo University · FDA-approved active Small molecule Quality 2/100

Ketorolac 30 mg is a Small molecule drug developed by Cairo University. It is currently FDA-approved.

At a glance

Generic nameKetorolac 30 mg
SponsorCairo University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ketorolac 30 mg

What is Ketorolac 30 mg?

Ketorolac 30 mg is a Small molecule drug developed by Cairo University.

Who makes Ketorolac 30 mg?

Ketorolac 30 mg is developed and marketed by Cairo University (see full Cairo University pipeline at /company/cairo-university).

What development phase is Ketorolac 30 mg in?

Ketorolac 30 mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing